Monoclonal antibodies

#Alzheimer's #Antibodies #Monoclonal antibodies #Neurodegenerative disorders #Therapeutic Antibodies

Therapeutic antibodies in the fight against Alzheimer’s

ImmunoBrain Checkpoint (IBC) is currently dosing patients in a clinical trial with its monoclonal antibody for Alzheimer’s disease (AD). DDW’s Megan Thomas caught up with Professor Michal Schwartz to learn more about her work and the work being carried out by IBC. MT: Can you provide an overview of your… Read More

#Exclusive Content

#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Where is the opportunity in the therapeutic antibody market?

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News

Japanese flag
#Astellas Pharma #Gastrointestinal #Japan #Monoclonal antibodies #Oncology

Japan becomes first country to approve Astellas’ gastric cancer mAb

Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Vyloy (zolbetuximab), an anti-claudin 18.2 (CLDN18.2) monoclonal antibody for patients with CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer. Vyloy is the first and only CLDN18.2-targeted therapy approved by any regulatory agency in the world. Gastric cancer is the third… Read More

#News #Regulatory

#Covid-19 #Covid-19 treatment #FDA #Invivyd #Monoclonal antibodies

FDA approves Covid-19 mAb for emergency use

The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) to half-life extended monoclonal antibody (mAb) Pemgarda (pemivibart, or VYD222) for the pre-exposure prophylaxis (prevention) of Covid-19. It is approved in adults and adolescents (12 years of age and older weighing at least… Read More

#News

EBV virus
#Epstein-Barr virus #Immunology / Virology & Vaccines #Monoclonal antibodies #National Institute of Allergy and Infectious Diseases

Monoclonal antibody could protect against Epstein-Barr virus

Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for the virus. The research was led by Jeffrey Cohen and colleagues from the National Institute of Allergy… Read More

#News

Monoclonal antibodies
#Antibody discovery workflow #Antibody-based therapeutics #App note #Biologics #Monoclonal antibodies

App Note: How Merck creates developability profiles for mAbs

Download this new Application Note to discover how the Protein Sciences group at Merck & Co. builds developability profiles for their monoclonal antibody variants. Get an in-depth explanation of the experiments they set up to obtain parameters that help them decide which candidates have the best potential to reach… Read More

#News

#Antibody discovery workflow #Antibody-based therapeutics #Biologics #Monoclonal antibodies

Biologics developability: How Merck creates developability profiles for their mAbs

In this Application Note, discover how the Protein Sciences group at Merck & Co. builds developability profiles for their monoclonal antibody variants. Get an in-depth explanation of the experiments they set up to obtain parameters that help them decide which candidates have the best potential to reach the market, and how they… Read More

#Resources

Monoclonal antibody
#Autoimmune disease #ImmunAbs #Monoclonal antibodies #Phase I trial

C5-targetting monoclonal antibody clears Phase I trials

Biotechnology company ImmunAbs has announced the successful completion of a Phase I clinical trial for IM-101, a humanised monoclonal antibody targeting complement C5. The complement system is widely acknowledged for its critical involvement in autoimmune diseases. The randomised, double-blind, placebo-controlled trial was conducted to… Read More

#News

2024 predictions, road forward
#2024 predictions #BioSenic #Cytiva #Monoclonal antibodies #Sphere Fluidics #TrakCel

2024 predictions: Experts comment on monoclonal antibodies 

DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes. Here, experts weigh in on the future of monoclonal antibodies (mAbs).  Amanda Halford, President Bioprocess, Cytiva  “In… Read More

#Exclusive Content #Trends & Analysis

#Antibodies #Bispecific Antibodies #FDA #Monoclonal antibodies #Neuroscience #Oncology

New DDW Highlights podcast: 11 March 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  It was antibodies hitting the headlines this week, with the discovery of antibodies with… Read More

#News

#Antibodies #Bispecific Antibodies #FDA #Monoclonal antibodies #Neuroscience #Oncology

This week in drug discovery (4-8 March) 

News round-up for 4-8 March by DDW Digital Content Editor Diana Spencer. It was antibodies hitting the headlines this week, with the discovery of antibodies with potential against a new influenza target, the launch of a Phase I trial to investigate a novel type of bispecific antibody, and… Read More

#News

#Collaboration #Fibrocor Therapeutics #Monoclonal antibodies #Phase I trial

New R&D collaboration to advance Alport Syndrome programme

Fibrocor Therapeutics has entered into a research and development (R&D) collaboration with the McQuade Center for Strategic Research and Development (MSRD) to advance its Alport Syndrome programme. The agreement includes a single digit million US$ upfront payment and additional funding that has the potential to cover the cost of studies… Read More

#Business & Investment #News

Peanut butter
#Allergy #FDA #Monoclonal antibodies #National Institute of Allergy and Infectious Diseases #Phase III trial

FDA approves first medication to reduce allergic reactions

The US Food and Drug Administration (FDA) has approved monoclonal antibody Xolair (omalizumab) for immunoglobulin E-mediated food allergy in some adults and children one year or older for the reduction of allergic reactions (Type I). The FDA said that Xolair is intended for repeated use to reduce the risk of… Read More

#News #Regulatory

#Biologics #Dermatology #Fibrotic disease #Immuno-dermatology #Monoclonal antibodies #Wound care

New DDW Highlights podcast: 19 February 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week our news highlights focus on skin conditions, with positive updates on hidradenitis… Read More

#News

#Biologics #Dermatology #Fibrotic disease #Immuno-dermatology #Monoclonal antibodies #Wound care

This week in drug discovery (12-16 February) 

News round-up for 12-16 February by DDW Digital Content Editor Diana Spencer. This week our news highlights focus on skin conditions, with positive updates on hidradenitis suppurativa, systemic sclerosis, wound-healing, and other dermatological conditions like atopic dermatitis and vitiligo. The top stories: Dual-action treatment… Read More

#News

Monoclonal antibodies
#Clinical trial #Dermatology #Monoclonal antibodies #Phase III trial #UCB

Monoclonal antibody improves hidradenitis suppurativa by 55%

UCB has revealed new data demonstrating a 55% improvement in adults with moderate to severe hidradenitis suppurativa (HS) treated with monoclonal antibody bimekizumab. The data were presented at the 13th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) in Lyon, France (7-9 February). Emmanuel… Read More

#News